Madan Jagasia, MD

Articles by Madan Jagasia, MD

Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC

ByHak Choy, MD,Anuradha Chakravarthy, MD,Russell Devore Iii, MD,Madan Jagasia, MD,Kenneth R. Hande, MD,John R. Roberts, MD,David H. Johnson, MD,Furhan Yunus, MD

July 2nd 2000

In preclinical studies, the topoisomerase I inhibitor irinotecan (Camptosar, CPT-11) has demonstrated activity as a radiosensitizer, probably due to its ability to inhibit potentially lethal radiation damage repair. We conducted a

Latest Updated Articles

Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC
Published: July 2nd 2000 | Updated:

Madan Jagasia, MD

Articles by Madan Jagasia, MD

Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC

Latest Updated Articles

Trending on CancerNetwork

ADCE-D01 Earns FDA Fast Track Designation in Soft Tissue Sarcoma

Serplulimab Plus Chemo Meets EFS End Point in Early-Stage Gastric Cancer

KRd Appears to Exhibit Greater Outcomes in Standard-Risk Multiple Myeloma

The Show and After Show Previews the 2025 ESMO Annual Congress

KRd-Based Quadruplets May “Eliminate” Transplant Need for Multiple Myeloma